PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry

Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Tretschock LM, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tauber N, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack C, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Michel LL, Wallwiener M, Fasching P, Schneeweiss A, Maurer C (2026)

Publication Type: Journal article

Publication year: 2026

Journal

Book Volume: 12

Article Number: 60

Journal Issue: 1

DOI: 10.1038/s41523-026-00947-8

Abstract

Germline BRCA1 and BRCA2 mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were introduced into clinical practice in 2018. Limited evidence about their routine clinical use highlights the importance of this analysis. We provide a real-world analysis for PARP-inhibitor use in ABC patients treated within the prospective German PRAEGNANT registry (NCT02338167). 152 patients with ABC receiving a PARP-inhibitor were included. Real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) were calculated for all patients using the Kaplan–Meier method. Subgroups (line of therapy, metastasis timing, hormone receptor (HR) status, treatment: olaparib, talazoparib, among others), germline BRCA1, BRCA2 and PALB2 mutations and adverse events (AEs) were analyzed. The median rwPFS was 6.2 months (95% CI, 4.8–7.9) and the median rwOS was 17.1 months (95% CI, 14.4–22.3). Line of therapy, HR status and treatment (olaparib versus talazoparib) appeared to especially affect both rwPFS and rwOS. Among patients with a reported germline mutation, 36.1% had a BRCA1, 62.9% a BRCA2 and 1.0% a PALB2 mutation. In summary, outcomes were comparable to those reported in pivotal trials despite later-line use of PARP-inhibitors in this analysis.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Halle (Saale) Germany (DE) Universitätsklinikum Regensburg Germany (DE) Universitätsklinikum Ulm Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Augsburg Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Eberhard Karls Universität Tübingen Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsklinikum Mannheim / University Medical Centre Mannheim (Universitätsmedizin Mannheim) Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Universitätsklinikum Köln Germany (DE) Frankfurter Hormon und Osteoporosezentrum Germany (DE) Städtische Kliniken Esslingen Germany (DE) Marienhospital Bottrop Germany (DE) Medizinische Hochschule Brandenburg "Theodor Fontane" / Brandenburg Medical School "Theodor Fontane" Germany (DE) St. Josefs-Krankenhaus Salzkotten Germany (DE) Agaplesion Markus Krankenhaus Germany (DE) ClinSol GmbH & Co.KG Germany (DE) Heinrich-Heine-Universität Düsseldorf Germany (DE) Klinikum rechts der Isar Germany (DE)

How to cite

APA:

Hörner, M., Hartkopf, A., John, N., Ziegler, P., Häberle, L., Uhrig, S.,... Maurer, C. (2026). PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry. npj Breast Cancer, 12(1). https://doi.org/10.1038/s41523-026-00947-8

MLA:

Hörner, Manuel, et al. "PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry." npj Breast Cancer 12.1 (2026).

BibTeX: Download